379 related articles for article (PubMed ID: 33232824)
1. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
2. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
[TBL] [Abstract][Full Text] [Related]
3. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
[No Abstract] [Full Text] [Related]
4. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
[TBL] [Abstract][Full Text] [Related]
5. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
6. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
[TBL] [Abstract][Full Text] [Related]
7. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.
Kong D; Jiang Y; Miao X; Wu Z; Liu H; Gong W
Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166267. PubMed ID: 34508829
[TBL] [Abstract][Full Text] [Related]
9. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
[TBL] [Abstract][Full Text] [Related]
11. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
[TBL] [Abstract][Full Text] [Related]
12. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
Moya IM; Castaldo SA; Van den Mooter L; Soheily S; Sansores-Garcia L; Jacobs J; Mannaerts I; Xie J; Verboven E; Hillen H; Algueró-Nadal A; Karaman R; Van Haele M; Kowalczyk W; De Waegeneer M; Verhulst S; Karras P; van Huffel L; Zender L; Marine JC; Roskams T; Johnson R; Aerts S; van Grunsven LA; Halder G
Science; 2019 Nov; 366(6468):1029-1034. PubMed ID: 31754005
[TBL] [Abstract][Full Text] [Related]
13. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma.
Liu P; Zhang H; Liang X; Ma H; Luan F; Wang B; Bai F; Gao L; Ma C
Oncotarget; 2015 Oct; 6(30):29048-59. PubMed ID: 26315112
[TBL] [Abstract][Full Text] [Related]
14. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
15. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
16. Loss of TAZ after YAP deletion severely impairs foregut development and worsens cholestatic hepatocellular injury.
Gabdulkhakova A; Krutsenko Y; Zhu J; Liu S; Poddar M; Singh S; Ma X; Nejak-Bowen K; Monga SPS; Molina LM
Hepatol Commun; 2023 Sep; 7(9):. PubMed ID: 37556373
[TBL] [Abstract][Full Text] [Related]
17. Two Hippo signaling modules orchestrate liver size and tumorigenesis.
Qi S; Zhong Z; Zhu Y; Wang Y; Ma M; Wang Y; Liu X; Jin R; Jiao Z; Zhu R; Sha Z; Dang K; Liu Y; Lim DS; Mao J; Zhang L; Yu FX
EMBO J; 2023 Jun; 42(11):e112126. PubMed ID: 36919851
[TBL] [Abstract][Full Text] [Related]
18. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
[TBL] [Abstract][Full Text] [Related]
20. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.
Jeong SH; Kim HB; Kim MC; Lee JM; Lee JH; Kim JH; Kim JW; Park WY; Kim SY; Kim JB; Kim H; Kim JM; Choi HS; Lim DS
J Clin Invest; 2018 Mar; 128(3):1010-1025. PubMed ID: 29400692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
